$AHAC I think humacyte has got a lot of potential from what looks to be a lead in a blue ocean market and the type of winner takes most scenario that Cathy woods believes in. Bio-med is relatively high on risk-reward basis, as it’s still product pending. They have a strong team, deep sector expertise, and a strategic investor/ springboard partner to roll out and push economies of scale, but ultimately don’t put all your eggs in one basket. As promising as the product is, still at phase 3 trials
$AHAC anything confirmed to the Wood prediction or just wishing? Just bought at 15.40, left some cash to average down if necessary
View original message